drugset / Trial / NCT06393166
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
It is a single arm, open-label, multicenter, phase II cinical trial to evaluate the efficacy and safety of the Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection in first-line treatment of patients with Advanced or Metastatic Pancreatic Cancer.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2025-05-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1 g | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Background | Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection | Unknown | 400 mg/m2 | Intravenous |
| Background | Serplulimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |